A Study to Evaluate the Effect of a Test (Sodium Bicarbonate) Toothpaste on the Oral Microbiome

NCT ID: NCT07273539

Last Updated: 2025-12-09

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 55 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-10-27
• Study Completion Date: 2026-02-28

Brief Summary

The aim of this 12-week clinical study is to evaluate the effect of a toothpaste containing sodium bicarbonate over time on the oral microbiome and to explore its effect in comparison to a regular fluoride toothpaste in participants with localized gingivitis.

Detailed Description

This will be a single-center, 12-week, randomized, controlled, single-blind (examiner only), two-treatment arm, parallel group design, clinical study investigating the effect of a toothpaste containing sodium bicarbonate on the oral microbiome in healthy adult participants with mild-moderate gingivitis. Approximately 55 participants (approximately 27 per group) will be randomized to ensure approximately 50 evaluable participants (approximately 25 per group) complete the study.

Conditions

Gingivitis

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

Test Toothpaste

Participants will be instructed to brush their teeth with the test toothpaste for at least one minute twice daily (morning and evening) for 12 weeks.

Group Type: EXPERIMENTAL

Sodium Bicarbonate Toothpaste

Intervention Type: DRUG

A toothpaste containing sodium bicarbonate and sodium fluoride.

Reference Toothpaste

Participants will be instructed to brush their teeth with the reference toothpaste for at least one minute twice daily (morning and evening) for 12 weeks.

Group Type: ACTIVE_COMPARATOR

Sodium Fluoride Toothpaste

Intervention Type: DRUG

A toothpaste containing 0.315 percent (%) weight/weight (w/w) sodium fluoride; 1450 parts per million (ppm) fluoride.

Interventions

Sodium Bicarbonate Toothpaste

A toothpaste containing sodium bicarbonate and sodium fluoride.

Intervention Type: DRUG

Sodium Fluoride Toothpaste

A toothpaste containing 0.315 percent (%) weight/weight (w/w) sodium fluoride; 1450 parts per million (ppm) fluoride.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Participant provision of a signed and dated informed consent document indicating that the participant has been informed of all pertinent aspects of the study before any assessment is performed.
• Participant's biological sex at birth was male or female.
• Participant who, at the time of screening is aged 18-65 years, inclusive.
• A participant who is willing and able to comply with scheduled visits, treatment plan and other study procedures.
• A participant in good general and mental health with, in the opinion of the investigator or medically qualified designee, no clinically significant or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
• Participant with at least 20 natural, permanent teeth (excluding 3rd molars) and with at least 40 evaluable surfaces.
• A healthy participant with mild to moderate gingivitis in the opinion of the clinical examiner.

Exclusion Criteria

• A participant who is an employee of the investigational site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
• A participant who has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
• A participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
• A participant who has any other clinical serious or unstable conditions (example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) which could have affected study out comes and/or participant safety.
• A participant who is a pregnant female (self-reported) at screening or baseline visit or intending to become pregnant over the duration of the study or who is breastfeeding.
• A participant with known or suspected intolerance or hypersensitivity to the study materials (or closely related compounds) or any of their stated ingredients.
• A participant unwilling or unable to comply with the Lifestyle Considerations described in this protocol (these will be added in the full protocol).
• A participant who is a current smoker or an ex-smoker (including vaper) who stopped within 6 months of Screening.
• A participant who is using smokeless forms of tobacco (example, chewing tobacco, gutkha, pan containing tobacco, nicotine-based e-cigarettes).
• A participant who is diagnosed with oral dryness or is taking any medication that in the view of the investigator is causing oral dryness.
• A participant who has a medical condition which could have directly influenced gingival bleeding.
• A participant who has a bleeding disorder that could have affected study outcomes and/or participant safety.
• A participant who has a recent history (within the last year) of alcohol or other substance abuse.
• A participant who has a severe oral condition (example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
• Presence of a tongue or lip piercing, or any other oral feature that could interfere with the usage of a toothbrush.
• A participant using any antibiotic and/or probiotic medication within 28 days prior to screening or at any time during the study.
• Participant who has used an oral care product containing anti-bacterial (example, chlorhexidine), probiotic or other ingredient that, in the opinion of the investigator or dentally qualified designee, could affect plaque formation or gingival health within 4 weeks of Screening or between Screening and the Baseline visit.
• A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
• A participant currently taking an anti-inflammatory medication which, in the opinion of the Investigator, could affect gingival condition.
• A participant currently taking a systemic medication (example, anti-inflammatory, anticoagulant, immunosuppressants) or traditional/herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
• A participant who shows signs of periodontitis or is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.
• A participant who has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice.
• A participant who has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
• A participant who has dentures (partial or full).
• A participant who has Fixed orthodontic appliances or is undergoing active or recent (within 3 months of Screening) orthodontic treatment, which in the opinion of the investigator, could interfere with study procedures, assessments or outcomes.
• A participant who has other orthodontic devices (example, bands, fixed retainers, or removable retainers) that could, in the opinion of the investigator, interferes with study procedures, assessment or outcomes.
• A participant who has numerous restorations in a poor state of repair.
• A participant who has any dental condition (example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
• A participant who has had dental prophylaxis within 12 weeks of Screening.
• A participant who has had teeth bleaching within 12 weeks of Screening.
• A participant who has high levels of extrinsic stain or calculus deposits
• A participant who has previously been enrolled in this study.
• A participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

HALEON

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Praveen Sharma

Role: PRINCIPAL_INVESTIGATOR

University of Birmingham

Locations

University of Birmingham

Birmingham, , United Kingdom

Site Status: RECRUITING

Countries

United Kingdom

Central Contacts

Haleon Response Center

Role: CONTACT

ww.clinical-trial-register@haleon.com

+441932959500

Facility Contacts

Praveen Sharma

Role: primary

Other Identifiers

400039

Identifier Type: -

Identifier Source: org_study_id